Literature DB >> 28169880

Blood pressure reduction in acute ischemic stroke according to time to treatment: a subgroup analysis of the China Antihypertensive Trial in Acute Ischemic Stroke trial.

Tan Xu1, Yonghong Zhang, Xiaoqing Bu, Dali Wang, Yingxian Sun, Chung-Shiuan Chen, Jinchao Wang, Hao Peng, Zhong Ju, Yanbo Peng, Tian Xu, Qunwei Li, Deqin Geng, Jintao Zhang, Dong Li, Fengshan Zhang, Libing Guo, Xuemei Wang, Yong Cui, Yongqiu Li, Dihui Ma, Dongsheng Zhang, Guang Yang, Yanjun Gao, Xiaodong Yuan, Jing Chen, Jiang He.   

Abstract

OBJECTIVE: The optimal time to initiate antihypertensive therapy among patients with acute ischemic stroke remains uncertain. We tested the effects of blood pressure reduction among patients with acute ischemic stroke according to time from onset to initiation of antihypertensive treatment.
METHODS: We randomly assigned 4071 acute ischemic stroke patients with elevated SBP to receive antihypertensive treatment or to discontinue all antihypertensive medications during hospitalization. The primary outcome was a combination of death and major disability, and secondary outcomes included the modified Rankin score, recurrent stroke, vascular disease events, and all-cause mortality.
RESULTS: At 24 h after randomization, the differences in SBP reductions were 8.7, 9.5, and 9.6 mmHg between the antihypertensive treatment and control groups among patients receiving treatment within less than 12, 12-23, and 24-48 h after stroke onset, respectively (P < 0.001 in all subgroups). At day 14 or hospital discharge, the primary and secondary outcomes were not significantly different between the treatment and control groups in all subgroups. At the 3-month follow-up, death or major disability [odds ratio (OR) 0.73; 95% confidence interval (CI) 0.55-0.96; P = 0.03], recurrent stroke (OR 0.25; 95% CI 0.08-0.74; P = 0.01), and vascular events (OR 0.41; 95% CI 0.18-0.95; P = 0.04) were significantly reduced in the antihypertensive treatment group only among participants who received treatment between 24 and 48 h.
CONCLUSION: Blood pressure reduction might reduce 3-month death and major disability and recurrent stroke among patients with acute ischemic stroke who receive antihypertensive treatment between 24 and 48 h after stroke onset. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01840072.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28169880      PMCID: PMC5785332          DOI: 10.1097/HJH.0000000000001288

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  22 in total

1.  Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research.

Authors:  Thomas G Pickering; John E Hall; Lawrence J Appel; Bonita E Falkner; John Graves; Martha N Hill; Daniel W Jones; Theodore Kurtz; Sheldon G Sheps; Edward J Roccella
Journal:  Hypertension       Date:  2004-12-20       Impact factor: 10.190

2.  Probability tables for individual comparisons by ranking methods.

Authors:  F WILCOXIN
Journal:  Biometrics       Date:  1947-09       Impact factor: 2.571

3.  Lowering blood pressure in acute stroke: the SCAST trial.

Authors:  Graeme J Hankey
Journal:  Lancet       Date:  2011-02-26       Impact factor: 79.321

4.  Blood pressure management in early ischemic stroke.

Authors:  Jeffrey L Saver
Journal:  JAMA       Date:  2014-02-05       Impact factor: 56.272

5.  Ordinal regression models for epidemiologic data.

Authors:  B G Armstrong; M Sloan
Journal:  Am J Epidemiol       Date:  1989-01       Impact factor: 4.897

6.  Factors influencing admission blood pressure levels in patients with acute stroke.

Authors:  B Carlberg; K Asplund; E Hägg
Journal:  Stroke       Date:  1991-04       Impact factor: 7.914

7.  Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial.

Authors:  John F Potter; Thompson G Robinson; Gary A Ford; Amit Mistri; Martin James; Julia Chernova; Carol Jagger
Journal:  Lancet Neurol       Date:  2008-12-04       Impact factor: 44.182

8.  Association of hypertension with stroke recurrence depends on ischemic stroke subtype.

Authors:  Yilong Wang; Jie Xu; Xingquan Zhao; David Wang; Chunxue Wang; Liping Liu; Anxin Wang; Xia Meng; Hao Li; Yongjun Wang
Journal:  Stroke       Date:  2013-02-26       Impact factor: 7.914

9.  The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.

Authors:  Else Charlotte Sandset; Philip M W Bath; Gudrun Boysen; Dalius Jatuzis; Janika Kõrv; Stephan Lüders; Gordon D Murray; Przemyslaw S Richter; Risto O Roine; Andreas Terént; Vincent Thijs; Eivind Berge
Journal:  Lancet       Date:  2011-02-26       Impact factor: 79.321

10.  Effect of Hyperacute Administration (Within 6 Hours) of Transdermal Glyceryl Trinitrate, a Nitric Oxide Donor, on Outcome After Stroke: Subgroup Analysis of the Efficacy of Nitric Oxide in Stroke (ENOS) Trial.

Authors:  Lisa Woodhouse; Polly Scutt; Kailash Krishnan; Eivind Berge; John Gommans; George Ntaios; Joanna Wardlaw; Nikola Sprigg; Philip M Bath
Journal:  Stroke       Date:  2015-10-13       Impact factor: 7.914

View more
  8 in total

Review 1.  Antihypertensive therapy in acute ischemic stroke: where do we stand?

Authors:  Eleni Georgianou; Panagiotis I Georgianos; Konstantinos Petidis; Vasilios G Athyros; Pantelis A Sarafidis; Asterios Karagiannis
Journal:  J Hum Hypertens       Date:  2018-09-19       Impact factor: 3.012

Review 2.  Acute Blood Pressure Management in Acute Ischemic Stroke and Spontaneous Cerebral Hemorrhage.

Authors:  Mollie McDermott; Cemal B Sozener
Journal:  Curr Treat Options Neurol       Date:  2018-08-18       Impact factor: 3.598

3.  Early antihypertensive treatment and clinical outcomes in acute ischemic stroke: subgroup analysis by baseline blood pressure.

Authors:  William J He; Chongke Zhong; Tan Xu; Dali Wang; Yingxian Sun; Xiaoqing Bu; Chung-Shiuan Chen; Jinchao Wang; Zhong Ju; Qunwei Li; Jintao Zhang; Deqin Geng; Jianhui Zhang; Dong Li; Yongqiu Li; Xiaodong Yuan; Yonghong Zhang; Tanika N Kelly
Journal:  J Hypertens       Date:  2018-06       Impact factor: 4.844

4.  Optimal blood pressure after reperfusion therapy in patients with acute ischemic stroke.

Authors:  Kang-Ho Choi; Jae-Myung Kim; Ja-Hae Kim; Joon-Tae Kim; Man-Seok Park; Seong-Min Choi; Seung-Han Lee; Byeong C Kim; Myeong-Kyu Kim; Ki-Hyun Cho
Journal:  Sci Rep       Date:  2019-04-05       Impact factor: 4.379

5.  Immediate Antihypertensive Treatment for Patients With Acute Ischemic Stroke With or Without History of Hypertension: A Secondary Analysis of the CATIS Randomized Clinical Trial.

Authors:  Rui Zhang; Chongke Zhong; Yonghong Zhang; Xuewei Xie; Zhengbao Zhu; Aili Wang; Chung-Shiuan Chen; Yanbo Peng; Hao Peng; Qunwei Li; Zhong Ju; Deqin Geng; Jing Chen; Liping Liu; Yilong Wang; Tan Xu; Jiang He
Journal:  JAMA Netw Open       Date:  2019-07-03

6.  Withdrawal of antihypertensive drugs in older people.

Authors:  Emily Reeve; Vanessa Jordan; Wade Thompson; Mouna Sawan; Adam Todd; Todd M Gammie; Ingrid Hopper; Sarah N Hilmer; Danijela Gnjidic
Journal:  Cochrane Database Syst Rev       Date:  2020-06-10

7.  Acute blood pressure levels and long-term outcome in ischemic stroke.

Authors:  Johan-Emil Bager; Clara Hjalmarsson; Karin Manhem; Bjorn Andersson
Journal:  Brain Behav       Date:  2018-05-18       Impact factor: 2.708

8.  China Antihypertensive Trial in Acute Ischemic Stroke II (CATIS-2): rationale and design.

Authors:  Liping Liu; Yilong Wang; Xuewei Xie; Dacheng Liu; Aili Wang; Penglian Wang; Suwen Shen; Chongke Zhong; Yufei Wei; Tan Xu; Yuesong Pan; Yong Jiang; Xia Meng; David Wang; Yonghong Zhang; Jiang He; Yongjun Wang
Journal:  Stroke Vasc Neurol       Date:  2021-03-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.